SAFETY DATA SHEET

Buprenorphine Liquid Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Buprenorphine Liquid Formulation

Manufacturer or supplier’s details
Company: MSD
Address: Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil 13106-054
Telephone: 908-740-4000
Emergency telephone: 55 19 3758 2000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Not a hazardous substance or mixture.

GHS label elements in accordance with ABNT NBR 14725 Standard
Not a hazardous substance or mixture.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Hydrochloride</td>
<td>53152-21-9</td>
<td>Acute toxicity (Oral), Category 3 Reproductive toxicity, Category 1A Specific target organ toxicity - single exposure, Category 3 Short-term (acute) aquatic hazard, Category 2 Long-term (chronic) aquatic hazard, Category 2</td>
<td>&gt;= 0,025 &lt; 0,1</td>
</tr>
</tbody>
</table>

1 / 12
SAFETY DATA SHEET

Buprenorphine Liquid Formulation

SECTION 4. FIRST AID MEASURES

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: None known.
Protection of first-aiders: No special precautions are necessary for first aid responders.
Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
Hazardous combustion products: Carbon oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
- Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine Hydrochloride</td>
<td>53152-21-9</td>
<td>TWA</td>
<td>0.2 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>2 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
- Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

**Personal protective equipment**

**Respiratory protection**: No personal respiratory protective equipment normally required.

**Hand protection**

- **Material**: Chemical-resistant gloves
- **Remarks**: Consider double gloving.

**Eye protection**

- **Material**: Wear safety glasses with side shields or goggles.
- **Remarks**: If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**

- **Material**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance**: liquid
- **Color**: No data available
- **Odor**: No data available
- **Odor Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
SAFETY DATA SHEET

Buprenorphine Liquid Formulation

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapor pressure: No data available

Relative vapor density: No data available

Relative density: No data available

Density: No data available

Solubility(ies)
   Water solubility: No data available

Partition coefficient: n-octanol/water: Not applicable

Autoignition temperature: No data available

Decomposition temperature: No data available

Viscosity
   Viscosity, kinematic: No data available

Explosive properties: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.

Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.

Chemical stability: Stable under normal conditions.

Possibility of hazardous reactions: Can react with strong oxidizing agents.

Conditions to avoid: None known.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
   Inhalation
   Skin contact
   Ingestion
   Eye contact

Acute toxicity
Not classified based on available information.
Components:

Buprenorphine Hydrochloride:
Acute oral toxicity: LD50 (Mouse): 261 mg/kg
LD50 (Rat): 600 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available
Acute toxicity (other routes of administration): LD50 (Rat): 31 mg/kg
Application Route: Intravenous
LD50 (Mouse): 24 mg/kg
Application Route: Intravenous

Skin corrosion/irritation
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Remarks: No data available

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Remarks: No data available

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Remarks: No data available

Germ cell mutagenicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal
Test Type: Chromosomal aberration
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Species: Rat
Application Route: Oral
Exposure time: 27 Months
LOAEL: 56 mg/kg body weight
Result: positive
Target Organs: Testes
Remarks: The significance of these findings for humans is not certain.

Species: Mouse
Application Route: Oral
Exposure time: 86 weeks
NOAEL: 100 mg/kg body weight
Result: negative
Carcinogenicity - Assessment:
Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Effects on fertility:
Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 80 mg/kg body weight
Result: No effects on fertility.

Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 5 mg/kg body weight
Result: No effects on fertility.

Test Type: Fertility
Species: Rabbit
Application Route: Oral  
Fertility: LOAEL: 1 mg/kg body weight  
Result: Preimplantation loss.

Test Type: Fertility  
Species: Rabbit  
Application Route: Intravenous  
Fertility: LOAEL: 0.2 mg/kg body weight  
Result: Postimplantation loss.

Effects on fetal development:

Test Type: Development  
Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 5 mg/kg body weight  
Result: Embryo-fetal toxicity., No teratogenic effects., Skeletal malformations.

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 160 mg/kg body weight  
Result: No effects on fetal development.

Test Type: Development  
Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 0.1 mg/kg body weight  
Result: Effects on newborn.

Test Type: Development  
Species: Rabbit  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 5 mg/kg body weight  
Result: Embryo-fetal toxicity., Skeletal malformations.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Result: Embryo-fetal toxicity., Skeletal malformations.

Reproductive toxicity - Assessment:  
May damage the unborn child. Suspected of damaging fertility.

STOT-single exposure
Not classified based on available information.

Components:

Buprenorphine Hydrochloride:
Assessment:  
May cause drowsiness or dizziness.

STOT-repeated exposure
Not classified based on available information.
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Buprenorphine Hydrochloride:
Inhalation: Target Organs: Central nervous system
Symptoms: Drowsiness, sedation, Headache, Nausea, Vomiting, Dizziness, Vertigo, Sweating, constipation, insomnia, Pain, respiratory depression, constriction of pupils, decrease in heart rate, Lowered blood pressure
Remarks: May cause neonatal withdrawal

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Buprenorphine Hydrochloride:
Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 6.25 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.319 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.137 mg/l
Exposure time: 28 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.883 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

LOEC (Daphnia magna (Water flea)): 1.95 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms: EC50: 588 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 135 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Persistence and degradability

**Components:**

**Buprenorphine Hydrochloride:**

Biodegradability: Result: Not readily biodegradable.

Bioaccumulative potential

**Components:**

**Buprenorphine Hydrochloride:**

Bioaccumulation: Species: Oncorhynchus mykiss (rainbow trout)

Bioconcentration factor (BCF): 0.4
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water: log Pow: 3.11

**Mobility in soil**

**Components:**

**Buprenorphine Hydrochloride:**

Distribution among environmental compartments: log Koc: 4.11

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods**

Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION**

**International Regulations**

**UNRTDG**
Not regulated as a dangerous good

**IATA-DGR**
Not regulated as a dangerous good

**IMDG-Code**
Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**Domestic regulation**

**ANTT**
SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH)  :  Not applicable

Brazil. List of chemicals controlled by the Federal Police  :  Not applicable

International Regulations

The ingredients of this product are reported in the following inventories:

- AICS  :  not determined
- DSL  :  not determined
- IECSC  :  not determined

SECTION 16. OTHER INFORMATION

Further information


Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Develop-
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

BR / Z8